Press releases
- Veeva to Present at Upcoming Investor Conferences
- Veeva Announces Fiscal 2025 First Quarter Results
- New Veeva Pulse Findings Show Connected Engagement Creates an Advantage as HCP Access Drops
- For the Second Year in a Row, Veeva MedTech Named Best Overall Medtech Software
- Biopharma Leaders Shape the Future of Drug Development at Veeva R&D and Quality Summit Europe
- Veeva Introduces Vault Basics for Biotechs
- Veeva to Release Fiscal 2025 First Quarter Results on May 30, 2024
- Top Biopharma Brands Reach Audiences 10x More Qualified with Veeva Crossix Prime Segments
- Veeva Launches AI Partner Program
- Veeva Announces Vault CRM Campaign Manager
More ▼
Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | -- |
Average volume | -- |
---|---|
Shares outstanding | 161.38m |
Free float | 146.92m |
P/E (TTM) | 49.81 |
Market cap | 28.12bn USD |
EPS (TTM) | 3.50 USD |
--
More ▼